MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
1.070
+0.030
+2.88%
Pre Market: 1.090 +0.02 +1.87% 08:56 12/04 EST
OPEN
1.020
PREV CLOSE
1.040
HIGH
1.090
LOW
0.9800
VOLUME
9.66K
TURNOVER
0
52 WEEK HIGH
7.17
52 WEEK LOW
0.9100
MARKET CAP
138.31M
P/E (TTM)
-0.9472
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MCRB last week (1127-1201)?
Weekly Report · 4h ago
SunPower: Not Yet Done
Sunpower is majority-owned (50.7%) by totalenergies and has a strong presence in the us domestic solar and energy management scene. Sunpower is a seeking alpha quant "strong sell" with 36.9% of the shares shorted. Solar pv has a big future and household solar is just starting in the united states.
Seeking Alpha · 6d ago
Weekly Report: what happened at MCRB last week (1120-1124)?
Weekly Report · 11/27 09:06
MCRB, CYTO and TGS among mid-day movers
Mira pharmaceuticals and ypf adr are among the gainers in mid-day movers. Mcrb, cyto and tgs among the losers. A number of companies reported positive results for the third quarter of the year. The sa daily news has a weekly newsquiz to test your knowledge of stocks.
Seeking Alpha · 11/20 17:59
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers cardio diagnostics hldgs (nasdaq:cdio) shares moved upwards by 74.2% to $1.73 during monday's regular session. Mira pharmaceuticals and altamira therapeutics shares increased by 46.34% and 41.23% respectively. Nanostring technologies stock decreased by 50.0% during the session.
Benzinga · 11/20 17:31
Weekly Report: what happened at MCRB last week (1113-1117)?
Weekly Report · 11/20 09:06
Weekly Report: what happened at MCRB last week (1106-1110)?
Weekly Report · 11/13 09:06
Seres Therapeutics: Much Better Risk-Reward At Current Price, But Still Risky
Seres therapeutics has reduced workforce by 41% and announced strategic restructuring. Restructuring will allow seres to focus on vowst commercialization and extend cash runaway into q4 2024. Mcrb's only approved product is a microbiome-based therapy for prevention of recurrent c. Difficile infection. Seres remains a risky investment pending more updates on commercial uptake and payer coverage.
Seeking Alpha · 11/12 07:01
More
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics company. The Company is developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead product candidate, SER-109, is designed to reduce further recurrence of CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by restructuring the gastrointestinal microbiome and modulating the metabolic landscape to address CDI. Building upon SER-109, it is developing microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and GvHD in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.